Peter Diamandis - Jun 21, 2022 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role
Director
Signature
/s/ Rene Paula Molina, attorney-in-fact for Peter Diamandis
Stock symbol
VAXX
Transactions as of
Jun 21, 2022
Transactions value $
$0
Form type
4
Date filed
6/23/2022, 07:58 PM
Previous filing
Jun 23, 2022
Next filing
Jul 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VAXX Class A common stock 431K Jun 21, 2022 Direct
holding VAXX Class A common stock 13.8K Jun 21, 2022 Held by spouse F4
holding VAXX Class B common stock 1.1M Jun 21, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAXX Stock option (right to buy) Award $0 +129K $0.00 129K Jun 21, 2022 Class A common stock 129K $2.09 Direct F1, F2, F3
holding VAXX Stock option (right to buy) 779K Jun 21, 2022 Class A common stock 779K $1.21 Direct F5
holding VAXX Stock option (right to buy) 528K Jun 21, 2022 Class A common stock 528K $0.57 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
F2 These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date.
F3 These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
F4 These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest.
F5 Represents 779,142 time-vesting options. These options are subject to a four year vesting schedule, beginning on December 31, 2019, vesting in equal installments each month during the vesting period.
F6 Represents 528,046 time-vesting options. These options are subject to a four-year vesting schedule, with 25% having vested on 6/2/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.